Mersana Therapeutics/MRSN

$4.27

4.18%
-
1D1W1MYTD1YMAX

About Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. The Company lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase I clinical trial evaluating UpRi in combination with carboplatin, and UP-NEXT, a Phase III clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Its pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Ticker

MRSN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Martin Huber

Employees

228

Headquarters

Cambridge, United States

MRSN Metrics

BasicAdvanced
$457.01M
Market cap
-
P/E ratio
-$1.78
EPS
1.38
Beta
-
Dividend rate

What the Analysts think about MRSN

Analyst Ratings

Majority rating from 9 analysts.
Hold

Price Targets

Average projection from 4 analysts.
29.74% downside
High $5.00
Low $1.00
$4.27
Current price
$3.00
Average price target

MRSN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-547.36% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$7.6M
-28.3%
Net income
$-41.6M
-23.39%
Profit margin
-547.36%
6.85%

MRSN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.29%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.44
-$0.52
-$0.47
-$0.35
-
Expected
-$0.50
-$0.44
-$0.44
-$0.36
-$0.16
Surprise
-12.77%
19.33%
6.47%
-3.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Mersana Therapeutics stock

Buy or sell Mersana Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing